1 1038 141 CLINACANTHUS NUTANS EXTRACTS MODULATE EPIGENETIC LINK TO CYTOSOLIC PHOSPHOLIPASE A2 EXPRESSION IN SH-SY5Y CELLS AND PRIMARY CORTICAL NEURONS. CLINACANTHUS NUTANS LINDAU (C. NUTANS), COMMONLY KNOWN AS SABAH SNAKE GRASS IN SOUTHEAST ASIA, IS WIDELY USED IN FOLK MEDICINE DUE TO ITS ANALGESIC, ANTIVIRAL, AND ANTI-INFLAMMATORY PROPERTIES. OUR RECENT STUDY PROVIDED EVIDENCE FOR THE REGULATION OF CYTOSOLIC PHOSPHOLIPASE A2 (CPLA2) MRNA EXPRESSION BY EPIGENETIC FACTORS (TAN ET AL. IN MOL NEUROBIOL. DOI: 10.1007/S12035-015-9314-Z , 2015). THIS ENZYME CATALYZES THE RELEASE OF ARACHIDONIC ACID FROM GLYCEROPHOSPHOLIPIDS, AND FORMATION OF PRO-INFLAMMATORY EICOSANOIDS OR TOXIC LIPID PEROXIDATION PRODUCTS SUCH AS 4-HYDROXYNONENAL. IN THIS STUDY, WE EXAMINED THE EFFECTS OF C. NUTANS ETHANOL LEAF EXTRACTS ON EPIGENETIC REGULATION OF CPLA2 MRNA EXPRESSION IN SH-SY5Y HUMAN NEUROBLASTOMA CELLS AND MOUSE PRIMARY CORTICAL NEURONS. C. NUTANS MODULATED INDUCTION OF CPLA2 EXPRESSION IN SH-SY5Y CELLS BY HISTONE DEACETYLASE (HDAC) INHIBITORS, MS-275, MC-1568, AND TSA. C. NUTANS EXTRACTS ALSO INHIBITED HISTONE ACETYLASE (HAT) ACTIVITY. LEVELS OF CPLA2 MRNA EXPRESSION WERE INCREASED IN PRIMARY CORTICAL NEURONS SUBJECTED TO 0.5-H OXYGEN-GLUCOSE DEPRIVATION INJURY (OGD). THIS INCREASE WAS SIGNIFICANTLY INHIBITED BY C. NUTANS TREATMENT. TREATMENT OF PRIMARY NEURONS WITH THE HDAC INHIBITOR MS-275 AUGMENTED OGD-INDUCED CPLA2 MRNA EXPRESSION, AND THIS INCREASE WAS MODULATED BY C. NUTANS EXTRACTS. OGD-STIMULATED INCREASE IN CPLA2 MRNA EXPRESSION WAS ALSO REDUCED BY A TIP60 HAT INHIBITOR, NU9056. IN VIEW OF A KEY ROLE OF CPLA2 IN THE PRODUCTION OF PRO-INFLAMMATORY EICOSANOIDS AND FREE RADICAL DAMAGE, AND THE FACT THAT EPIGENETIC EFFECTS ON GENES ARE OFTEN LONG-LASTING, RESULTS SUGGEST A ROLE FOR C. NUTANS AND PHYTOCHEMICALS TO INHIBIT THE PRODUCTION OF ARACHIDONIC ACID-DERIVED PRO-INFLAMMATORY EICOSANOIDS AND CHRONIC INFLAMMATION, THROUGH EPIGENETIC REGULATION OF CPLA2 EXPRESSION. 2016 2 2311 56 EPIGENETIC REGULATION OF CYTOSOLIC PHOSPHOLIPASE A2 IN SH-SY5Y HUMAN NEUROBLASTOMA CELLS. GROUP IVA CYTOSOLIC PHOSPHOLIPASE A2 (CPLA2 OR PLA2G4A) IS A KEY ENZYME THAT CONTRIBUTES TO INFLAMMATION VIA THE GENERATION OF ARACHIDONIC ACID AND EICOSANOIDS. WHILE MUCH IS KNOWN ABOUT REGULATION OF CPLA2 BY POSTTRANSLATIONAL MODIFICATION SUCH AS PHOSPHORYLATION, LITTLE IS KNOWN ABOUT ITS EPIGENETIC REGULATION. IN THIS STUDY, TREATMENT WITH HISTONE DEACETYLASE (HDAC) INHIBITORS, TRICHOSTATIN A (TSA), VALPROIC ACID, TUBACIN AND THE CLASS I HDAC INHIBITOR, MS-275, WERE FOUND TO INCREASE CPLA2ALPHA MESSENGER RNA (MRNA) EXPRESSION IN SH-SY5Y HUMAN NEUROBLASTOMA CELLS. CO-TREATMENT OF THE HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR, ANACARDIC ACID, MODULATED UPREGULATION OF CPLA2ALPHA INDUCED BY TSA. SPECIFIC INVOLVEMENT OF CLASS I HDACS AND HAT IN CPLA2ALPHA REGULATION WAS FURTHER SHOWN, AND A TIP60-SPECIFIC HAT INHIBITOR, NU9056, MODULATED THE UPREGULATION OF CPLA2ALPHA INDUCED BY MS-275. IN ADDITION, CO-TREATMENT OF WITH HISTONE METHYLTRANSFERASE (HMT) INHIBITOR, 5'-DEOXY-5'-METHYLTHIOADENOSINE (MTA) SUPPRESSED TSA-INDUCED CPLA2ALPHA UPREGULATION. THE ABOVE CHANGES IN CPLA2 MRNA EXPRESSION WERE REFLECTED AT THE PROTEIN LEVEL BY WESTERN BLOTS AND IMMUNOCYTOCHEMISTRY. CHROMATIN IMMUNOPRECIPITATION (CHIP) SHOWED TSA INCREASED BINDING OF TRIMETHYLATED H3K4 TO THE PROXIMAL PROMOTER REGION OF THE CPLA2ALPHA GENE. CELL INJURY AFTER TSA TREATMENT AS INDICATED BY LACTATE DEHYDROGENASE (LDH) RELEASE WAS MODULATED BY ANACARDIC ACID, AND A ROLE OF CPLA2 IN MEDIATING TSA-INDUCED INJURY SHOWN, AFTER CO-INCUBATION WITH THE CPLA2 SELECTIVE INHIBITOR, ARACHIDONOYL TRIFLUOROMETHYL KETONE (AACOCF3). TOGETHER, RESULTS INDICATE EPIGENETIC REGULATION OF CPLA2 AND THE POTENTIAL OF SUCH REGULATION FOR TREATMENT OF CHRONIC INFLAMMATION. 2016 3 6434 30 THE VON HIPPEL LINDAU TUMOUR SUPPRESSOR GENE IS A NOVEL TARGET OF E2F4-MEDIATED TRANSCRIPTIONAL REPRESSION IN PREECLAMPSIA. THE VON HIPPEL LINDAU TUMOUR SUPPRESSOR (VHL) PROTEIN IS ESSENTIAL FOR PROPER PLACENTAL DEVELOPMENT AND IS DOWNREGULATED IN PREECLAMPSIA (PE), A DEVASTATING DISORDER OF PREGNANCY TYPIFIED BY CHRONIC HYPOXIA. TO DATE, KNOWLEDGE ON VHL GENETIC AND EPIGENETIC REGULATION IS RESTRICTED TO INACTIVATING MUTATIONS AND LOSS-OF-HETEROZYGOSITY IN RENAL CELL CARCINOMAS. HEREIN, WE SOUGHT TO EXAMINE WHETHER VHL DNA IS SUBJECT TO DIFFERENTIAL METHYLATION, AND IF SO, WHETHER IT IS ALTERED IN EARLY-ONSET PE (E-PE). SODIUM BISULFITE MODIFICATION AND METHYLATION-SPECIFIC PCR ANALYSIS REVEALED THAT VHL IS SUBJECT TO EXTENSIVE METHYLATION IN A CPG-RICH REGION WITHIN ITS PROMOTER IN THE HUMAN PLACENTA. NOTABLY, WE DETECTED SIGNIFICANT DIFFERENCES IN METHYLATION IN E-PE PLACENTAE RELATIVE TO NORMOTENSIVE AGE-MATCHED CONTROLS AT KEY TRANSCRIPTION FACTOR BINDING SITES, INCLUDING THAT OF THE TRANSCRIPTIONAL REPRESSOR E2F4. TREATMENT OF JEG3 CELLS WITH 5-AZA-2'-DEOXYCYTIDINE, REVEALED THAT LOSS OF DNA METHYLATION PROMOTED VHL TRANSCRIPTION BY ATTENUATING VHL ASSOCIATION WITH E2F4. RNAI KNOCKDOWN OF E2F4 IN VITRO CONFIRMED ITS FUNCTION ON VHL REPRESSION. EXPOSURE OF JEG3 CELLS TO TRANSFORMING GROWTH FACTOR BETA (TGFBETA) DOWNREGULATED VHL MRNA. IN LINE WITH ELEVATED LEVELS OF TGFBETA3 IN E-PE, CHROMATIN IMMUNOPRECIPITATION ASSAYS REVEALED THAT E2F4-VHL ASSOCIATION WAS ENHANCED UPON TGFBETA3 TREATMENT, INDICATIVE OF VHL TRANSCRIPTIONAL INHIBITION. IN LINE WITH DECREASED VHL EXPRESSION IN E-PE, AUGMENTED E2F4-VHL ASSOCIATION WAS ALSO OBSERVED IN E-PE PLACENTAL TISSUE RELATIVE TO CONTROLS. IN CONCLUSION, WE DEMONSTRATE FOR THE FIRST TIME THAT HYPOMETHYLATION OF VHL DNA AT A KEY TRANSCRIPTION FACTOR BINDING SITE HAS SIGNIFICANT CONSEQUENCES FOR ITS TRANSCRIPTIONAL REPRESSION IN EARLY-ONSET PREECLAMPSIA. 2018 4 6767 25 ZNF382 CONTROLS MOUSE NEUROPATHIC PAIN VIA SILENCER-BASED EPIGENETIC INHIBITION OF CXCL13 IN DRG NEURONS. NERVE INJURY-INDUCED CHANGES OF GENE EXPRESSION IN DORSAL ROOT GANGLION (DRG) ARE CRITICAL FOR NEUROPATHIC PAIN GENESIS. HOWEVER, HOW THESE CHANGES OCCUR REMAINS ELUSIVE. HERE WE REPORT THE DOWN-REGULATION OF ZINC FINGER PROTEIN 382 (ZNF382) IN INJURED DRG NEURONS AFTER NERVE INJURY. RESCUING THIS DOWN-REGULATION ATTENUATES NOCICEPTIVE HYPERSENSITIVITY. CONVERSELY, MIMICKING THIS DOWN-REGULATION PRODUCES NEUROPATHIC PAIN SYMPTOMS, WHICH ARE ALLEVIATED BY C-X-C MOTIF CHEMOKINE 13 (CXCL13) KNOCKDOWN OR ITS RECEPTOR CXCR5 KNOCKOUT. MECHANISTICALLY, AN IDENTIFIED CIS-ACTING SILENCER AT DISTAL UPSTREAM OF THE CXCL13 PROMOTER SUPPRESSES CXCL13 TRANSCRIPTION VIA BINDING TO ZNF382. BLOCKING THIS BINDING OR GENETICALLY DELETING THIS SILENCER ABOLISHES THE ZNF382 SUPPRESSION ON CXCL13 TRANSCRIPTION AND IMPAIRS ZNF382-INDUCED ANTINOCICEPTION. MOREOVER, ZNF382 DOWN-REGULATION DISRUPTS THE REPRESSIVE EPIGENETIC COMPLEX CONTAINING HISTONE DEACETYLASE 1 AND SET DOMAIN BIFURCATED 1 AT THE SILENCER-PROMOTER LOOP, RESULTING IN CXCL13 TRANSCRIPTIONAL ACTIVATION. THUS, ZNF382 DOWN-REGULATION IS REQUIRED FOR NEUROPATHIC PAIN LIKELY THROUGH SILENCER-BASED EPIGENETIC DISINHIBITION OF CXCL13, A KEY NEUROPATHIC PAIN PLAYER, IN DRG NEURONS. 2021 5 2482 31 EPIGENETIC UPREGULATION OF METABOTROPIC GLUTAMATE RECEPTOR 2 IN THE SPINAL CORD ATTENUATES OESTROGEN-INDUCED VISCERAL HYPERSENSITIVITY. OBJECTIVE: EPIGENETIC MECHANISMS ARE POTENTIAL TARGETS TO RELIEVE SOMATIC PAIN. HOWEVER, LITTLE IS KNOWN WHETHER EPIGENETIC REGULATION INTERFERES WITH VISCERAL PAIN. PREVIOUS STUDIES SHOW THAT OESTROGEN FACILITATES VISCERAL PAIN. THIS STUDY AIMED TO DETERMINE WHETHER HISTONE HYPERACETYLATION IN THE SPINAL CORD COULD ATTENUATE OESTROGEN-FACILITATED VISCERAL PAIN. DESIGN: THE EFFECT OF THE HISTONE DEACETYLASE INHIBITOR SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) ON THE MAGNITUDE OF THE VISCEROMOTOR RESPONSE (VMR) TO COLORECTAL DISTENTION WAS EXAMINED IN OVARIECTOMISED RATS WITH/WITHOUT OESTROGEN REPLACEMENT. AN ADDITIONAL INTERACTION WITH THE METABOTROPIC GLUTAMATE RECEPTOR 2/3 (MGLUR2/3) ANTAGONIST LY341495 WAS TESTED. THE LEVELS OF ACETYLATED HISTONE AND MGLUR2 MRNA AND PROTEIN WERE ANALYSED. THE BINDING OF ACETYLATED H3 AND OESTROGEN RECEPTOR ALPHA (ERALPHA) TO THE GRM2 PROMOTER WAS MEASURED BY CHROMATIN IMMUNOPRECIPITATION COUPLED WITH QPCR. RESULTS: IN OVARIECTOMISED RATS, 17BETA-ESTRADIOL (E2), BUT NOT SAFFLOWER OIL, INCREASED THE MAGNITUDE OF THE VMR TO COLORECTAL DISTENTION. SAHA ATTENUATED THE E2-FACILITATED VMR, BUT HAD NO EFFECT IN SAFFLOWER OIL-TREATED RATS. SUBSEQUENT SPINAL ADMINISTRATION OF LY341495 REVERSED THE ANTINOCICEPTIVE EFFECT OF SAHA IN E2 RATS. IN ADDITION, SAHA INCREASED MGLUR2 MRNA AND PROTEIN IN THE SPINAL DORSAL HORN FOLLOWING E2, BUT NOT VEHICLE, TREATMENT. IN CONTRAST, NEITHER E2 NOR SAHA ALONE ALTERED MGLUR2 MRNA. SAHA INCREASED BINDING OF H3K9AC AND ERALPHA TO THE SAME REGIONS OF THE GRM2 PROMOTER IN E2-SAHA-TREATED ANIMALS. CONCLUSIONS: HISTONE HYPERACETYLATION IN THE SPINAL CORD ATTENUATES THE PRONOCICEPTIVE EFFECTS OF OESTROGEN ON VISCERAL SENSITIVITY, SUGGESTING THAT EPIGENETIC REGULATION MAY BE A POTENTIAL APPROACH TO RELIEVE VISCERAL PAIN. 2015 6 400 35 ANALGESIA INDUCED BY THE EPIGENETIC DRUG, L-ACETYLCARNITINE, OUTLASTS THE END OF TREATMENT IN MOUSE MODELS OF CHRONIC INFLAMMATORY AND NEUROPATHIC PAIN. BACKGROUND L-ACETYLCARNITINE, A DRUG MARKETED FOR THE TREATMENT OF CHRONIC PAIN, CAUSES ANALGESIA BY EPIGENETICALLY UP-REGULATING TYPE-2 METABOTROPIC GLUTAMATE (MGLU2) RECEPTORS IN THE SPINAL CORD. BECAUSE THE EPIGENETIC MECHANISMS ARE TYPICALLY LONG-LASTING, WE HYPOTHESIZED THAT ANALGESIA COULD OUTLAST THE DURATION OF L-ACETYLCARNITINE TREATMENT IN MODELS OF INFLAMMATORY AND NEUROPATHIC PAIN. RESULTS A SEVEN-DAY TREATMENT WITH L-ACETYLCARNITINE (100 MG/KG, ONCE A DAY, I.P.) PRODUCED AN ANTIALLODYNIC EFFECT IN THE COMPLETE FREUND ADJUVANT MOUSE MODEL OF CHRONIC INFLAMMATORY PAIN. L-ACETYLCARNITINE-INDUCED ANALGESIA PERSISTED FOR AT LEAST 14 DAYS AFTER DRUG WITHDRAWAL. IN CONTRAST, THE ANALGESIC EFFECT OF PREGABALIN, AMITRYPTILINE, CEFTRIAXONE, AND N-ACETYLCYSTEINE DISAPPEARED SEVEN DAYS AFTER DRUG WITHDRAWAL. L-ACETYLCARNITINE TREATMENT ENHANCED MGLU2/3 RECEPTOR PROTEIN LEVELS IN THE DORSAL REGION OF THE SPINAL CORD. THIS EFFECT ALSO PERSISTED FOR TWO WEEKS AFTER DRUG WITHDRAWAL AND WAS ASSOCIATED WITH INCREASED LEVELS OF ACETYLATED HISTONE H3 BOUND TO THE GRM2 GENE PROMOTER IN THE DORSAL ROOT GANGLIA. A LONG-LASTING ANALGESIC EFFECT OF L-ACETYLCARNITINE WAS ALSO OBSERVED IN MICE SUBJECTED TO CHRONIC CONSTRICTION INJURY OF THE SCIATIC NERVE. IN THESE ANIMALS, A 14-DAY TREATMENT WITH PREGABALIN, AMITRYPTILINE, TRAMADOL, OR L-ACETYLCARNITINE PRODUCED A SIGNIFICANT ANTIALLODYNIC EFFECT, WITH PREGABALIN DISPLAYING THE GREATEST EFFICACY. IN MICE TREATED WITH PREGABALIN, TRAMADOL OR L-ACETYLCARNITINE THE ANALGESIC EFFECT WAS STILL VISIBLE 15 DAYS AFTER THE END OF DRUG TREATMENT. HOWEVER, ONLY IN MICE TREATED WITH L-ACETYLCARNITINE ANALGESIA PERSISTED 37 DAYS AFTER DRUG WITHDRAWAL. THIS EFFECT WAS ASSOCIATED WITH AN INCREASE IN MGLU2/3 RECEPTOR PROTEIN LEVELS IN THE DORSAL HORNS OF THE SPINAL CORD. CONCLUSIONS OUR FINDINGS SUGGEST THAT L-ACETYLCARNITINE HAS THE UNIQUE PROPERTY TO CAUSE A LONG-LASTING ANALGESIC EFFECT THAT MIGHT REDUCE RELAPSES IN PATIENTS SUFFERING FROM CHRONIC PAIN. 2017 7 742 33 CANNABINOID CB2 RECEPTORS ARE UPREGULATED VIA BIVALENT HISTONE MODIFICATIONS AND CONTROL PRIMARY AFFERENT INPUT TO THE SPINAL CORD IN NEUROPATHIC PAIN. TYPE-2 CANNABINOID RECEPTORS (CB2, ENCODED BY THE CNR2 GENE) ARE MAINLY EXPRESSED IN IMMUNE CELLS, AND CB2 AGONISTS NORMALLY HAVE NO ANALGESIC EFFECT. HOWEVER, NERVE INJURY UPREGULATES CB2 IN THE DORSAL ROOT GANGLION (DRG), FOLLOWING WHICH CB2 STIMULATION REDUCES NEUROPATHIC PAIN. IT IS UNCLEAR HOW NERVE INJURY INCREASES CB2 EXPRESSION OR HOW CB2 ACTIVITY IS TRANSFORMED IN NEUROPATHIC PAIN. IN THIS STUDY, IMMUNOBLOTTING SHOWED THAT SPINAL NERVE LIGATION (SNL) INDUCED A DELAYED AND SUSTAINED INCREASE IN CB2 EXPRESSION IN THE DRG AND DORSAL SPINAL CORD SYNAPTOSOMES. RNASCOPE IN SITU HYBRIDIZATION ALSO SHOWED THAT SNL SUBSTANTIALLY INCREASED CB2 MRNA LEVELS, MOSTLY IN MEDIUM AND LARGE DRG NEURONS. FURTHERMORE, WE FOUND THAT THE SPECIFIC CB2 AGONIST JWH-133 SIGNIFICANTLY INHIBITS THE AMPLITUDE OF DORSAL ROOT-EVOKED GLUTAMATERGIC EXCITATORY POSTSYNAPTIC CURRENTS IN SPINAL DORSAL HORN NEURONS IN SNL RATS, BUT NOT IN SHAM CONTROL RATS; INTRATHECAL INJECTION OF JWH-133 REVERSED PAIN HYPERSENSITIVITY IN SNL RATS, BUT HAD NO EFFECT IN SHAM CONTROL RATS. IN ADDITION, CHROMATIN IMMUNOPRECIPITATION-QPCR ANALYSIS SHOWED THAT SNL INCREASED ENRICHMENT OF TWO ACTIVATING HISTONE MARKS (H3K4ME3 AND H3K9AC) AND DIMINISHED OCCUPANCY OF TWO REPRESSIVE HISTONE MARKS (H3K9ME2 AND H3K27ME3) AT THE CNR2 PROMOTER IN THE DRG. IN CONTRAST, SNL HAD NO EFFECT ON DNA METHYLATION LEVELS AROUND THE CNR2 PROMOTER. OUR FINDINGS SUGGEST THAT PERIPHERAL NERVE INJURY PROMOTES CB2 EXPRESSION IN PRIMARY SENSORY NEURONS VIA EPIGENETIC BIVALENT HISTONE MODIFICATIONS AND THAT CB2 ACTIVATION REDUCES NEUROPATHIC PAIN BY ATTENUATING NOCICEPTIVE TRANSMISSION FROM PRIMARY AFFERENT NERVES TO THE SPINAL CORD. 2022 8 1120 35 COMPARISON OF DIFFERENT HISTONE DEACETYLASE INHIBITORS IN ATTENUATING INFLAMMATORY PAIN IN RATS. HISTONE DEACETYLASE INHIBITORS (HDACIS), WHICH INTERFERE WITH THE EPIGENETIC PROCESS OF HISTONE ACETYLATION, HAVE SHOWN ANALGESIC EFFECTS IN ANIMAL MODELS OF PERSISTENT PAIN. THE HDAC FAMILY COMPRISES 18 GENES; HOWEVER, THE DIFFERENT EFFECTS OF DISTINCT CLASSES OF HDACIS ON PAIN RELIEF REMAIN UNCLEAR. THE AIM OF THIS STUDY WAS TO DETERMINE THE EFFICACY OF THESE HDACIS ON ATTENUATING THERMAL HYPERALGESIA IN PERSISTENT INFLAMMATORY PAIN. PERSISTENT INFLAMMATORY PAIN WAS INDUCED BY INJECTING COMPLETE FREUND'S ADJUVANT (CFA) INTO THE LEFT HIND PAW OF RATS. THEN, HDACIS TARGETING CLASS I (ENTINOSTAT (MS-275)) AND CLASS IIA (SODIUM BUTYRATE, VALPROIC ACID (VPA), AND 4-PHENYLBUTYRIC ACID (4-PBA)), OR CLASS II (SUBEROYLANILIDE HYDOXAMIC ACID (SAHA), TRICHOSTATIN A (TSA), AND DACINOSTAT (LAQ824)) WERE ADMINISTERED INTRAPERITONEALLY ONCE DAILY FOR 3 OR 4 DAYS. WE FOUND THAT THE INJECTION OF SAHA ONCE A DAY FOR 3 DAYS SIGNIFICANTLY ATTENUATED CFA-INDUCED THERMAL HYPERALGESIA FROM DAY 4 AND LASTED 7 DAYS. IN COMPARISON WITH SAHA, SUPPRESSION OF HYPERALGESIA BY 4-PBA PEAKED ON DAY 2, WHEREAS THAT BY MS-275 OCCURRED ON DAYS 5 AND 6. FATIGUE WAS A SERIOUS SIDE EFFECT SEEN WITH MS-275. THESE FINDINGS WILL BE BENEFICIAL FOR OPTIMIZING THE SELECTION OF SPECIFIC HDACIS IN MEDICAL FIELDS SUCH AS PAIN MEDICINE AND NEUROPSYCHIATRY. 2019 9 687 40 BRAINSTEM BRAIN-DERIVED NEUROTROPHIC FACTOR SIGNALING IS REQUIRED FOR HISTONE DEACETYLASE INHIBITOR-INDUCED PAIN RELIEF. OUR PREVIOUS STUDY DEMONSTRATED THAT PERSISTENT PAIN CAN EPIGENETICALLY SUPPRESS THE TRANSCRIPTION OF GAD2 [ENCODING GLUTAMIC ACID DECARBOXYLASE 65 (GAD65)] AND CONSEQUENTLY IMPAIR THE INHIBITORY FUNCTION OF GABAERGIC SYNAPSES IN CENTRAL PAIN-MODULATING NEURONS. THIS CONTRIBUTES TO THE DEVELOPMENT OF PERSISTENT PAIN SENSITIZATION. HISTONE DEACETYLASE (HDAC) INHIBITORS INCREASED GAD65 ACTIVITY CONSIDERABLY, RESTORED GABA SYNAPTIC FUNCTION, AND RENDERED SENSITIZED PAIN BEHAVIOR LESS PRONOUNCED. HOWEVER, THE MOLECULAR MECHANISMS BY WHICH HDAC REGULATES GABAERGIC TRANSMISSION THROUGH GAD65 UNDER PAIN CONDITIONS ARE UNKNOWN. THIS WORK SHOWED THAT HDAC INHIBITOR-INDUCED INCREASES IN COLOCALIZATION OF GAD65 AND SYNAPTIC PROTEIN SYNAPSIN I ON THE PRESYNAPTIC AXON TERMINALS OF THE NUCLEUS RAPHE MAGNUS (NRM) WERE BLOCKED BY A TRKB RECEPTOR ANTAGONIST K252A [(9S,10R,12R)-2,3,9,10,11,12-HEXAHYDRO-10-HYDROXY-9-METHYL-1-OXO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-10-CARBOXYLIC ACID METHYL ESTER], INDICATING THAT BDNF-TRKB SIGNALING MAY BE REQUIRED IN GAD65 MODULATION OF GABA SYNAPTIC FUNCTION. AT THE BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) PROMOTER, HDAC INHIBITORS INDUCED SIGNIFICANT INCREASES IN H3 HYPERACETYLATION, CONSISTENT WITH THE INCREASE IN BDNF MRNA AND TOTAL PROTEINS. ALTHOUGH EXOGENOUS BDNF FACILITATED GABA MINIATURE INHIBITORY POSTSYNAPTIC CURRENTS AND GAD65 ACCUMULATION IN NRM NEURONAL SYNAPSES IN NORMAL RATS, IT FAILED TO DO SO IN ANIMALS SUBJECTED TO PERSISTENT INFLAMMATION. IN ADDITION, BLOCKADE OF THE TRKB RECEPTOR WITH K252A HAS NO EFFECT ON MINIATURE INHIBITORY POSTSYNAPTIC CURRENTS AND SYNAPTIC GAD65 ACCUMULATION UNDER NORMAL CONDITIONS. IN ADDITION, THE ANALGESIC EFFECTS OF HDAC INHIBITORS ON BEHAVIOR WERE BLOCKED BY NRM INFUSION OF K252A. THESE FINDINGS SUGGEST THAT BDNF-TRKB SIGNALING IS REQUIRED FOR DRUGS THAT REVERSE THE EPIGENETIC EFFECTS OF CHRONIC PAIN AT THE GENE LEVEL, SUCH AS HDAC INHIBITORS. 2015 10 2249 43 EPIGENETIC MODULATION OF MGLU2 RECEPTORS BY HISTONE DEACETYLASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY PAIN. KNOWING THAT EXPRESSION OF METABOTROPIC GLUTAMATE 2 (MGLU2) RECEPTORS IN THE DORSAL ROOT GANGLIA IS REGULATED BY ACETYLATION MECHANISMS, WE EXAMINED THE EFFECT OF TWO SELECTIVE AND CHEMICALLY UNRELATED HISTONE DEACETYLASE (HDAC) INHIBITORS, N-(2-AMINOPHENYL)-4-[N-(PYRIDINE-3-YLMETHOXY-CARBONYL)AMINOMETHYL]BENZAMIDE (MS-275) AND SUBEROYLANILIDE HYDROAMIC ACID (SAHA), IN A MOUSE MODEL OF PERSISTENT INFLAMMATORY PAIN. ALTHOUGH A SINGLE SUBCUTANEOUS INJECTION OF MS-275 (3 MG/KG) OR SAHA (5-50 MG/KG) WAS INEFFECTIVE, A 5-DAY TREATMENT WITH EITHER OF THE TWO HDAC INHIBITORS SUBSTANTIALLY REDUCED THE NOCICEPTIVE RESPONSE IN THE SECOND PHASE OF THE FORMALIN TEST, WHICH REFLECTS THE DEVELOPMENT OF CENTRAL SENSITIZATION IN THE DORSAL HORN OF THE SPINAL CORD. ANALGESIA WAS ABROGATED BY A SINGLE INJECTION OF THE MGLU2/3 RECEPTOR ANTAGONIST (ALPHAS)-ALPHA-AMINO-ALPHA-[(1S,2S)-2-CARBOXYCYCLOPROPYL]-9H-XANTINE-9-PROPANOIC ACID (LY341495; 1 MG/KG, I.P.), WHICH WAS INACTIVE PER SE. BOTH MS-275 AND SAHA UP-REGULATED THE EXPRESSION OF MGLU2 RECEPTORS IN THE DORSAL ROOT GANGLION (DRG) AND SPINAL CORD UNDER CONDITIONS IN WHICH THEY CAUSED ANALGESIA, WITHOUT CHANGING THE EXPRESSION OF MGLU1A, MGLU4, OR MGLU5 RECEPTORS. INDUCTION OF DRG MGLU2 RECEPTORS IN RESPONSE TO SAHA WAS ASSOCIATED WITH INCREASED ACETYLATION OF P65/RELA ON LYSINE 310, A PROCESS THAT ENHANCES THE TRANSCRIPTIONAL ACTIVITY OF P65/RELA AT NUCLEAR FACTOR-KAPPAB-REGULATED GENES. TRANSCRIPTION OF THE MGLU2 RECEPTOR GENE IS KNOWN TO BE ACTIVATED BY P65/RELA IN DRG NEURONS. WE CONCLUDE THAT HDAC INHIBITION PRODUCES ANALGESIA BY UP-REGULATING MGLU2 RECEPTOR EXPRESSION IN THE DRG, AN EFFECT THAT RESULTS FROM THE AMPLIFICATION OF NF-KAPPAB TRANSCRIPTIONAL ACTIVITY. THESE DATA PROVIDE THE FIRST EVIDENCE THAT HDAC INHIBITORS CAUSE ANALGESIA AND SUGGEST THAT HDACS ARE POTENTIAL TARGETS FOR THE EPIGENETIC TREATMENT OF PAIN. 2009 11 3196 28 HDAC INHIBITORS RESTORE C-FIBRE SENSITIVITY IN EXPERIMENTAL NEUROPATHIC PAIN MODEL. BACKGROUND AND PURPOSE: HYPOESTHESIA IS A CLINICAL FEATURE OF NEUROPATHIC PAIN. THE FEATURE IS PARTLY EXPLAINED BY THE EVIDENCE OF EPIGENETIC REPRESSION OF NAV 1.8 SODIUM CHANNEL IN THE DORSAL ROOT GANGLION (DRG). EXPERIMENTAL APPROACH: WE INVESTIGATED THE POSSIBILITY OF TRICHOSTATIN A (TSA), VALPROIC ACID (VPA) AND SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) TO REVERSE THE UNIQUE C-FIBRE SENSITIVITY OBSERVED FOLLOWING PARTIAL LIGATION OF SCIATIC NERVE IN MICE. KEY RESULTS: NERVE INJURY-INDUCED DOWN-REGULATION OF DRG NAV 1.8 SODIUM CHANNEL AND C-FIBRE-RELATED HYPOESTHESIA WERE REVERSED BY TSA, VPA AND SAHA TREATMENTS, WHICH INHIBIT HISTONE DEACETYLASE (HDAC), AND INCREASE HISTONE ACETYLATION AT THE REGULATORY SEQUENCE OF NAV 1.8. CONCLUSIONS AND IMPLICATIONS: TAKEN TOGETHER, THESE STUDIES PROVIDE THE EVIDENCE THAT HYPOESTHESIA AND UNDERLYING DOWN-REGULATION OF NAV 1.8, NEGATIVE SYMPTOMS OBSERVED IN NERVE INJURY-INDUCED NEUROPATHIC PAIN MODELS ARE REGULATED BY AN EPIGENETIC CHROMATIN REMODELLING THROUGH HDAC-RELATED MACHINERIES. 2013 12 2745 28 EXPRESS: HISTONE HYPERACETYLATION MODULATES SPINAL TYPE II METABOTROPIC GLUTAMATE RECEPTOR ALLEVIATING STRESS-INDUCED VISCERAL HYPERSENSITIVITY IN FEMALE RATS. STRESS IS OFTEN A TRIGGER TO EXACERBATE CHRONIC PAIN INCLUDING VISCERAL HYPERSENSITIVITY ASSOCIATED WITH IRRITABLE BOWEL SYNDROME, A FEMALE PREDOMINANT FUNCTIONAL BOWEL DISORDER. EPIGENETIC MECHANISMS THAT MEDIATE STRESS RESPONSES ARE A POTENTIAL TARGET TO INTERFERE WITH VISCERAL PAIN. THE PURPOSE OF THIS STUDY WAS TO EXAMINE THE EFFECT OF A HISTONE DEACETYLASE INHIBITOR, SUBEROYLANILIDE HYDROXAMIC ACID, ON VISCERAL HYPERSENSITIVITY INDUCED BY A SUBCHRONIC STRESSOR IN FEMALE RATS AND TO INVESTIGATE THE INVOLVEMENT OF SPINAL GLUTAMATE RECEPTORS. THREE DAILY SESSIONS OF FORCED SWIM INDUCED VISCERAL HYPERSENSITIVITY. INTRATHECAL SUBEROYLANILIDE HYDROXAMIC ACID PREVENTED OR REVERSED THE STRESS-INDUCED VISCERAL HYPERSENSITIVITY, INCREASED SPINAL HISTONE 3 ACETYLATION AND INCREASED MGLUR2 AND MGLUR3 EXPRESSION. CHROMATIN IMMUNOPRECIPITATION (CHIP) ANALYSIS REVEALED ENRICHMENT OF H3K9AC AND H3K18AC AT SEVERAL PROMOTER GRM2 AND GRM3 REGIONS. THE MGLUR2/3 ANTAGONIST LY341495 REVERSED THE INHIBITORY EFFECT OF SUBEROYLANILIDE HYDROXAMIC ACID ON THE STRESS-INDUCED VISCERAL HYPERSENSITIVITY. IN SURPRISING CONTRAST, STRESS AND/OR SUBEROYLANILIDE HYDROXAMIC ACID HAD NO EFFECT ON SPINAL NMDA RECEPTOR EXPRESSION OR FUNCTION. THESE DATA REVEAL HISTONE MODIFICATION MODULATES MGLUR2/3 EXPRESSION IN THE SPINAL CORD TO ATTENUATE STRESSINDUCED VISCERAL HYPERSENSITIVITY. HDAC INHIBITORS MAY PROVIDE A POTENTIAL APPROACH TO RELIEVE VISCERAL HYPERSENSITIVITY ASSOCIATED WITH IRRITABLE BOWEL SYNDROME. 2016 13 3191 38 HDAC AND HAT INHIBITORS DIFFERENTLY AFFECT ANALGESIA MEDIATED BY GROUP II METABOTROPIC GLUTAMATE RECEPTORS. BACKGROUND: HISTONE DEACETYLASES (HDACS) AND HISTONE ACETYLTRANSFERASES (HATS) ARE KEY PLAYERS IN EPIGENETIC REGULATION OF GENE EXPRESSION. ANALGESIC ACTIVITY BY HDAC INHIBITORS HAS BEEN REPORTED IN DIFFERENT PAIN MODELS INCLUDING INFLAMMATORY AND NEUROPATHIC PAIN. THESE DRUGS INTERFERE WITH GENE EXPRESSION THROUGH DIFFERENT MECHANISMS INCLUDING CHROMATIN REMODELING AND/OR ACTIVATION OF TRANSCRIPTION FACTORS. AMONG OTHER TARGETS, HDAC INHIBITORS REGULATE METABOTROPIC GLUTAMATE RECEPTORS TYPE 2 (MGLU2) EXPRESSION IN CENTRAL AND PERIPHERAL CENTRAL NERVOUS SYSTEM. HOWEVER WHETHER INHIBITION OF HAT ACTIVITY ALSO REGULATES MGLU2 EXPRESSION HAS NOT BEEN REPORTED. FINDINGS: HERE WE REPORT THAT CURCUMIN (CUR), A NATURALLY OCCURRING COMPOUND ENDOWED WITH P300/CREB-BINDING PROTEIN HAT INHIBITORY ACTIVITY, IS ABLE TO INDUCE A DRASTIC DOWN-REGULATION OF THE MGLU2 RECEPTOR IN THE MOUSE SPINAL CORD AFTER SYSTEMIC ADMINISTRATION TOGETHER WITH A MARKED HYPOACETYLATION OF HISTONES H3 AND H4 IN DORSAL ROOT GANGLIA (DRG). FURTHERMORE, THE ANALGESIC ACTIVITY OF THE MGLU2/3 AGONIST, LY379268 IS LOST AFTER A 3-DAY TREATMENT WITH CUR. CONVERSELY THE ANALGESIC ACTIVITY OF LY379268 IS POTENTIATED IN MICE PRETREATED FOR 5 CONSECUTIVE DAYS WITH THE HDAC INHIBITOR, SUBEROYLANILIDE HYDROXAMIC ACID (SAHA), KNOWN TO INDUCE MGLU2-UPREGULATION. CONCLUSIONS: OUR RESULTS DEMONSTRATE THAT SYSTEMICALLY INJECTED CUR IS ABLE TO INHIBIT H3 AND H4 ACETYLATION IN THE DRG AND TO DOWN-REGULATE MGLU2 RECEPTORS IN THE SPINAL CORD. WE ALSO DEMONSTRATE THAT LONG TERM MODIFICATION OF THE MGLU2 EXPRESSION AFFECTS THE ANALGESIC PROPERTIES OF THE ORTHOSTERIC MGLU2/3 AGONIST, LY379268. THESE DATA OPEN UP THE POSSIBILITY THAT EPIGENETIC MODULATORS MIGHT BE GIVEN IN COMBINATION WITH "TRADITIONAL" DRUGS IN A CONTEXT OF A MULTI TARGET APPROACH FOR A BETTER ANALGESIC EFFICACY. 2014 14 3332 30 HISTONE DEACETYLASE INHIBITOR-INDUCED EMERGENCE OF SYNAPTIC DELTA-OPIOID RECEPTORS AND BEHAVIORAL ANTINOCICEPTION IN PERSISTENT NEUROPATHIC PAIN. THE EFFICACY OF OPIOIDS IN PATIENTS WITH CHRONIC NEUROPATHIC PAIN REMAINS CONTROVERSIAL. ALTHOUGH ACTIVATION OF DELTA-OPIOID RECEPTORS (DORS) IN THE BRAINSTEM REDUCES INFLAMMATION-INDUCED PERSISTENT HYPERALGESIA, IT IS NOT EFFECTIVE UNDER PERSISTENT NEUROPATHIC PAIN CONDITIONS AND THESE CLINICAL PROBLEMS REMAIN LARGELY UNKNOWN. IN THIS STUDY, BY USING A CHRONIC CONSTRICTION INJURY (CCI) OF THE SCIATIC NERVE IN RATS, WE FOUND THAT IN THE BRAINSTEM NUCLEUS RAPHE MAGNUS (NRM), DORS EMERGED ON THE SURFACE MEMBRANE OF CENTRAL SYNAPTIC TERMINALS ON DAY 3 AFTER CCI SURGERY AND DISAPPEARED ON DAY 14. HISTONE DEACETYLASE (HDAC) INHIBITORS MICROINJECTED INTO THE NRM IN VIVO INCREASED THE LEVEL OF SYNAPTOSOMAL DOR PROTEIN AND NRM INFUSION OF DOR AGONISTS PRODUCING AN ANTINOCICEPTIVE EFFECT IN A NERVE GROWTH FACTOR (NGF) SIGNALING-DEPENDENT MANNER. IN VITRO, IN CCI RAT SLICES INCUBATED WITH HDAC INHIBITORS, DOR AGONISTS SIGNIFICANTLY INHIBITED EPSCS. THIS EFFECT WAS BLOCKED BY TYROSINE RECEPTOR KINASE A ANTAGONISTS. CHROMATIN IMMUNOPRECIPITATION ANALYSIS REVEALED THAT NRM INFUSION OF HDAC INHIBITORS IN CCI RATS INCREASED THE LEVEL OF HISTONE H4 ACETYLATION AT NGF GENE PROMOTER REGIONS. NGF WAS INFUSED INTO THE NRM OR INCUBATED CCI RAT SLICES DROVE DORS TO THE SURFACE MEMBRANE OF SYNAPTIC TERMINALS. TAKEN TOGETHER, EPIGENETIC UPREGULATION OF NGF ACTIVITY BY HDAC INHIBITORS IN THE NRM PROMOTES THE TRAFFICKING OF DORS TO PAIN-MODULATING NEURONAL SYNAPSES UNDER NEUROPATHIC PAIN CONDITIONS, LEADING TO DELTA-OPIOID ANALGESIA. THESE FINDINGS INDICATE THAT THERAPEUTIC USE OF DOR AGONISTS COMBINED WITH HDAC INHIBITORS MIGHT BE EFFECTIVE IN CHRONIC NEUROPATHIC PAIN MANAGEMENTS. 2016 15 4212 26 METHAMPHETAMINE DOWNREGULATES STRIATAL GLUTAMATE RECEPTORS VIA DIVERSE EPIGENETIC MECHANISMS. BACKGROUND: CHRONIC METHAMPHETAMINE (METH) EXPOSURE CAUSES NEUROADAPTATIONS AT GLUTAMATERGIC SYNAPSES. METHODS: TO IDENTIFY THE METH-INDUCED EPIGENETIC UNDERPINNINGS OF THESE NEUROADAPTATIONS, WE INJECTED INCREASING METH DOSES TO RATS FOR 2 WEEKS AND MEASURED STRIATAL GLUTAMATE RECEPTOR EXPRESSION. WE THEN QUANTIFIED THE EFFECTS OF METH EXPOSURE ON HISTONE ACETYLATION. WE ALSO MEASURED METH-INDUCED CHANGES IN DNA METHYLATION AND DNA HYDROXYMETHYLATION. RESULTS: CHRONIC METH DECREASED TRANSCRIPT AND PROTEIN EXPRESSION OF GLUA1 AND GLUA2 ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLE PROPIONIC ACID RECEPTOR (AMPAR) AND GLUN1 N-METHYL-D-ASPARTATE RECEPTOR SUBUNITS. THESE CHANGES WERE ASSOCIATED WITH ALTERED ELECTROPHYSIOLOGICAL GLUTAMATERGIC RESPONSES IN STRIATAL NEURONS. CHROMATIN IMMUNOPRECIPITATION-POLYMERASE CHAIN REACTION REVEALED THAT METH DECREASED ENRICHMENT OF ACETYLATED HISTONE H4 ON GLUA1, GLUA2, AND GLUN1 PROMOTERS. METHAMPHETAMINE EXPOSURE ALSO INCREASED REPRESSOR ELEMENT-1 SILENCING TRANSCRIPTION FACTOR (REST) COREPRESSOR 1, METHYLATED CPG BINDING PROTEIN 2, AND HISTONE DEACETYLASE 2 ENRICHMENT, BUT NOT OF SIRTUIN 1 OR SIRTUIN 2, ONTO GLUA1 AND GLUA2 GENE SEQUENCES. MOREOVER, METH CAUSED INTERACTIONS OF REST COREPRESSOR 1 AND METHYLATED CPG BINDING PROTEIN 2 WITH HISTONE DEACETYLASE 2 AND OF REST WITH HISTONE DEACETYLASE 1. SURPRISINGLY, METHYLATED DNA IMMUNOPRECIPITATION AND HYDROXYMETHYLATED DNA IMMUNOPRECIPITATION-POLYMERASE CHAIN REACTION REVEALED METH-INDUCED DECREASED ENRICHMENT OF 5-METHYLCYTOSINE AND 5-HYDROXYMETHYLCYTOSINE AT GLUA1 AND GLUA2 PROMOTER SEQUENCES. IMPORTANTLY, THE HISTONE DEACETYLASE INHIBITOR, VALPROIC ACID, BLOCKED METH-INDUCED DECREASED EXPRESSION OF AMPAR AND N-METHYL-D-ASPARTATE RECEPTOR SUBUNITS. FINALLY, VALPROIC ACID ALSO ATTENUATED METH-INDUCED DECREASE H4K16AC RECRUITMENT ON AMPAR GENE SEQUENCES. CONCLUSIONS: THESE OBSERVATIONS SUGGEST THAT HISTONE H4 HYPOACETYLATION MAY BE THE MAIN DETERMINANT OF METH-INDUCED DECREASED STRIATAL GLUTAMATE RECEPTOR EXPRESSION. 2014 16 5480 35 RESVERATROL REVERSES MORPHINE-INDUCED NEUROINFLAMMATION IN MORPHINE-TOLERANT RATS BY REVERSAL HDAC1 EXPRESSION. BACKGROUND/PURPOSE: WE PREVIOUSLY SHOWED THAT SUBSEQUENT INTRATHECAL (I.T.) INJECTION OF RESVERATROL (30 MUG) SIGNIFICANTLY REVERSES MORPHINE-EVOKED NEUROINFLAMMATION IN MORPHINE-TOLERANT RATS. THE PRESENT STUDY EXAMINED THE UNDERLYING MECHANISM. METHODS: MALE WISTAR RATS WERE IMPLANTED WITH TWO I.T. CATHETERS, ONE OF WHICH WAS CONNECTED TO A MINIOSMOTIC PUMP AND USED FOR MORPHINE (15 MUG/H) OR SALINE INFUSION FOR 120 HOURS. TO EXAMINE THE EFFECTS ON SPINAL CORD EXPRESSION OF HISTONE DEACETYLASE 1 (HDAC1), THE INFLAMMATORY CYTOKINE TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA), AND TNF RECEPTOR (TNFR) 1 AND TNFR2 DURING TOLERANCE INDUCTION, A TAIL-FLICK TEST WAS PERFORMED PRIOR TO INFUSION AND AFTER 24 HOURS, 48 HOURS, 72 HOURS, 96 HOURS, AND 120 HOURS OF INFUSION. RESULTS: RESVERATROL TREATMENT PRIOR TO MORPHINE CHALLENGE RESTORED THE ANTINOCICEPTIVE EFFECT OF MORPHINE IN MORPHINE-TOLERANT RATS AND REVERSED THE MORPHINE INFUSION-INDUCED INCREASE IN HDAC1, TNF-ALPHA, AND TNFR1 EXPRESSION. MOREOVER, CHRONIC MORPHINE INFUSION INCREASED TNFR1-SPECIFIC EXPRESSION IN NEURON IN MORPHINE-TOLERANT RAT SPINAL CORDS, AND THIS EFFECT WAS ALMOST COMPLETELY INHIBITED BY RESVERATROL TREATMENT PRIOR TO MORPHINE CHALLENGE. CONCLUSION: RESVERATROL RESTORES THE ANTINOCICEPTIVE EFFECT OF MORPHINE BY REVERSING MORPHINE INFUSION-INDUCED SPINAL CORD NEUROINFLAMMATION AND INCREASE IN TNFR1 EXPRESSION. THE REVERSAL OF THE MORPHINE-INDUCED INCREASE IN TNFR1 EXPRESSION BY RESVERATROL IS PARTIALLY DUE TO REVERSAL OF THE MORPHINE INFUSION-INDUCED INCREASE IN HDAC1 EXPRESSION. RESVERATROL PRETREATMENT CAN BE USED AS AN ADJUVANT IN CLINICAL PAIN MANAGEMENT FOR PATIENTS WHO NEED LONG-TERM MORPHINE TREATMENT OR WITH NEUROPATHIC PAIN. 2016 17 4616 30 NERVE INJURY INCREASES BRAIN-DERIVED NEUROTROPHIC FACTOR LEVELS TO SUPPRESS BK CHANNEL ACTIVITY IN PRIMARY SENSORY NEURONS. ABNORMAL HYPEREXCITABILITY OF PRIMARY SENSORY NEURONS CONTRIBUTES TO NEUROPATHIC PAIN DEVELOPMENT AFTER NERVE INJURY. NERVE INJURY PROFOUNDLY REDUCES THE EXPRESSION OF BIG CONDUCTANCE CA(2+) -ACTIVATED K(+) (BK) CHANNELS IN THE DORSAL ROOT GANGLION (DRG). HOWEVER, LITTLE IS KNOWN ABOUT HOW NERVE INJURY AFFECTS BK CHANNEL ACTIVITY IN DRG NEURONS. IN THIS STUDY, WE DETERMINED THE CHANGES IN BK CHANNEL ACTIVITY IN DRG NEURONS IN A RAT MODEL OF NEUROPATHIC PAIN AND THE CONTRIBUTION OF BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) TO REDUCED BK CHANNEL ACTIVITY. THE BK CHANNEL ACTIVITY WAS PRESENT PREDOMINANTLY IN SMALL AND MEDIUM DRG NEURONS, AND LIGATION OF L5 AND L6 SPINAL NERVES PROFOUNDLY DECREASED THE BK CURRENT DENSITY IN THESE NEURONS. BLOCKING BK CHANNELS SIGNIFICANTLY INCREASED NEURONAL EXCITABILITY IN SHAM CONTROL, BUT NOT IN NERVE-INJURED, RATS. THE BDNF CONCENTRATION IN THE DRG WAS SIGNIFICANTLY GREATER IN NERVE-INJURED RATS THAN IN CONTROL RATS. BDNF TREATMENT LARGELY REDUCED BK CURRENTS IN DRG NEURONS IN CONTROL RATS, WHICH WAS BLOCKED BY EITHER ANTI-BDNF ANTIBODY OR K252A, A TRK RECEPTOR INHIBITOR. FURTHERMORE, EITHER ANTI-BDNF ANTIBODY OR K252A REVERSED REDUCTION IN BK CURRENTS IN INJURED DRG NEURONS. BDNF TREATMENT REDUCED THE MRNA LEVELS OF BKALPHA1 SUBUNIT IN DRG NEURONS, AND ANTI-BDNF ANTIBODY ATTENUATED THE REDUCTION IN THE BKALPHA1 MRNA LEVEL IN INJURED DRG NEURONS. THESE FINDINGS SUGGEST THAT NERVE INJURY PRIMARILY DIMINISHES THE BK CHANNEL ACTIVITY IN SMALL AND MEDIUM DRG NEURONS. INCREASED BDNF LEVELS CONTRIBUTE TO REDUCED BK CHANNEL ACTIVITY IN DRG NEURONS THROUGH EPIGENETIC AND TRANSCRIPTIONAL MECHANISMS IN NEUROPATHIC PAIN. 2012 18 4172 26 MELATONIN IMPEDES TET1-DEPENDENT MGLUR5 PROMOTER DEMETHYLATION TO RELIEVE PAIN. MELATONIN (N-ACETYL-5-METHOXYTRYPTAMINE)/MT2 RECEPTOR-DEPENDENT EPIGENETIC MODIFICATION REPRESENTS A NOVEL PATHWAY IN THE TREATMENT OF NEUROPATHIC PAIN. BECAUSE SPINAL TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE 1 (TET1)-DEPENDENT EPIGENETIC DEMETHYLATION HAS RECENTLY BEEN LINKED TO PAIN HYPERSENSITIVITY, WE HYPOTHESIZED THAT MELATONIN/MT2-DEPENDENT ANALGESIA INVOLVES SPINAL TET1-DEPENDENT DEMETHYLATION. HERE, WE SHOWED THAT SPINAL TET1 GENE TRANSFER BY INTRATHECAL DELIVERY OF TET1-ENCODING VECTORS TO NAIVE RATS PRODUCED PROFOUND AND LONG-LASTING NOCICEPTIVE HYPERSENSITIVITY. IN ADDITION, ENHANCED TET1 EXPRESSION, TET1-METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 5 (MGLUR5) PROMOTER COUPLING, DEMETHYLATION AT THE MGLUR5 PROMOTER, AND MGLUR5 EXPRESSION IN DORSAL HORN NEURONS WERE OBSERVED. RATS SUBJECTED TO SPINAL NERVE LIGATION AND INTRAPLANTAR COMPLETE FREUND'S ADJUVANT INJECTION DISPLAYED TACTILE ALLODYNIA AND BEHAVIORAL HYPERALGESIA ASSOCIATED WITH SIMILAR CHANGES IN THE DORSAL HORN. NOTABLY, INTRATHECAL MELATONIN INJECTION REVERSED THE PROTEIN EXPRESSION, PROTEIN-PROMOTER COUPLING, PROMOTER DEMETHYLATION, AND PAIN HYPERSENSITIVITY INDUCED BY TET1 GENE TRANSFER, SPINAL NERVE LIGATION, AND INTRAPLANTAR COMPLETE FREUND'S ADJUVANT INJECTION. ALL THE EFFECTS CAUSED BY MELATONIN WERE BLOCKED BY PRETREATMENT WITH A MT2 RECEPTOR-SELECTIVE ANTAGONIST. IN CONCLUSION, MELATONIN RELIEVES PAIN BY IMPEDING TET1-DEPENDENT DEMETHYLATION OF MGLUR5 IN DORSAL HORN NEURONS THROUGH THE MT2 RECEPTOR. OUR FINDINGS LINK MELATONIN/MT2 SIGNALING TO TET1-DEPENDENT EPIGENETIC DEMETHYLATION OF NOCICEPTIVE GENES FOR THE FIRST TIME AND SUGGEST MELATONIN AS A PROMISING THERAPY FOR THE TREATMENT OF PAIN. 2017 19 4160 32 MECP2 EPIGENETIC SILENCING OF OPRM1 GENE IN PRIMARY SENSORY NEURONS UNDER NEUROPATHIC PAIN CONDITIONS. OPIOIDS ARE THE LAST OPTION FOR THE PHARMACOLOGICAL TREATMENT OF NEUROPATHIC PAIN, BUT THEIR ANTINOCICEPTIVE EFFECTS ARE LIMITED. DECREASED MU OPIOID RECEPTOR (MOR) EXPRESSION IN THE PERIPHERAL NERVOUS SYSTEM MAY CONTRIBUTE TO THIS. HERE, WE SHOWED THAT NERVE INJURY INDUCED HYPERMETHYLATION OF THE OPRM1 GENE PROMOTER AND AN INCREASED EXPRESSION OF METHYL-CPG BINDING PROTEIN 2 (MECP2) IN INJURED DORSAL ROOT GANGLION (DRG). THE DOWNREGULATION OF MOR IN THE DRG IS CLOSELY RELATED TO THE AUGMENTATION OF MECP2, AN EPIGENETIC REPRESSOR, WHICH COULD RECRUIT HDAC1 AND BIND TO THE METHYLATED REGIONS OF THE OPRM1 GENE PROMOTER. MECP2 KNOCKDOWN RESTORED THE EXPRESSION OF MOR IN INJURED DRG AND ENHANCED THE ANALGESIC EFFECT OF MORPHINE, WHILE THE MIMICKING OF THIS INCREASE VIA THE INTRATHECAL INFUSION OF VIRAL VECTOR-MEDIATED MECP2 WAS SUFFICIENT TO REDUCE MOR IN THE DRG. MOREOVER, HDAC1 INHIBITION WITH SUBEROYLANILIDE HYDROXAMIC ACID, AN HDAC INHIBITOR, ALSO PREVENTED MOR REDUCTION IN THE DRG OF NEUROPATHIC PAIN MICE, CONTRIBUTING TO THE AUGMENTATION OF MORPHINE ANALGESIA EFFECTS. MECHANISTICALLY, UPREGULATED MECP2 PROMOTES THE BINDING OF A HIGH LEVEL OF HDCA1 TO HYPERMETHYLATED REGIONS OF THE OPRM1 GENE PROMOTER, REDUCES THE ACETYLATION OF HISTONE H3 (ACH3) LEVELS OF THE OPRM1 GENE PROMOTER, AND ATTENUATES OPRM1 TRANSCRIPTION IN INJURED DRG. THUS, UPREGULATED MECP2 AND HDAC1 IN OPRM1 GENE PROMOTER SITES, NEGATIVELY REGULATES MOR EXPRESSION IN INJURED DRG, MITIGATING THE ANALGESIC EFFECT OF THE OPIOIDS. TARGETING MECP2/HDAC1 MAY THUS PROVIDE A NEW SOLUTION FOR IMPROVING THE THERAPEUTIC EFFECT OF OPIOIDS IN A CLINICAL SETTING. 2021 20 4615 37 NERVE INJURY DIMINISHES OPIOID ANALGESIA THROUGH LYSINE METHYLTRANSFERASE-MEDIATED TRANSCRIPTIONAL REPRESSION OF MU-OPIOID RECEPTORS IN PRIMARY SENSORY NEURONS. THE MU-OPIOID RECEPTOR (MOR, ENCODED BY OPRM1) AGONISTS ARE THE MAINSTAY ANALGESICS FOR TREATING MODERATE TO SEVERE PAIN. NERVE INJURY CAUSES DOWN-REGULATION OF MORS IN THE DORSAL ROOT GANGLION (DRG) AND DIMINISHES THE OPIOID EFFECT ON NEUROPATHIC PAIN. HOWEVER, THE EPIGENETIC MECHANISMS UNDERLYING THE DIMINISHED MOR EXPRESSION CAUSED BY NERVE INJURY ARE NOT CLEAR. G9A (ENCODED BY EHMT2), A HISTONE 3 AT LYSINE 9 METHYLTRANSFERASE, IS A KEY CHROMATIN REGULATOR RESPONSIBLE FOR GENE SILENCING. IN THIS STUDY, WE DETERMINED THE ROLE OF G9A IN DIMINISHED MOR EXPRESSION AND OPIOID ANALGESIC EFFECTS IN ANIMAL MODELS OF NEUROPATHIC PAIN. WE FOUND THAT NERVE INJURY IN RATS INDUCED A LONG-LASTING REDUCTION IN THE EXPRESSION LEVEL OF MORS IN THE DRG BUT NOT IN THE SPINAL CORD. NERVE INJURY CONSISTENTLY INCREASED THE ENRICHMENT OF THE G9A PRODUCT HISTONE 3 AT LYSINE 9 DIMETHYLATION IN THE PROMOTER OF OPRM1 IN THE DRG. G9A INHIBITION OR SIRNA KNOCKDOWN FULLY REVERSED MOR EXPRESSION IN THE INJURED DRG AND POTENTIATED THE MORPHINE EFFECT ON PAIN HYPERSENSITIVITY INDUCED BY NERVE INJURY. IN MICE LACKING EHMT2 IN DRG NEURONS, NERVE INJURY FAILED TO REDUCE THE EXPRESSION LEVEL OF MORS AND THE MORPHINE EFFECT. IN ADDITION, G9A INHIBITION OR EHMT2 KNOCKOUT IN DRG NEURONS NORMALIZED NERVE INJURY-INDUCED REDUCTION IN THE INHIBITORY EFFECT OF THE OPIOID ON SYNAPTIC GLUTAMATE RELEASE FROM PRIMARY AFFERENT NERVES. OUR FINDINGS INDICATE THAT G9A CONTRIBUTES CRITICALLY TO TRANSCRIPTIONAL REPRESSION OF MORS IN PRIMARY SENSORY NEURONS IN NEUROPATHIC PAIN. G9A INHIBITORS MAY BE USED TO ENHANCE THE OPIOID ANALGESIC EFFECT IN THE TREATMENT OF CHRONIC NEUROPATHIC PAIN. 2016